Sunday, May 2nd, 2021
8:30 – 10:45
Plenary Session 5: Bench to Bedside: New insights Into Hemostasis and Cancer
Chairs: P.M. Sandset (Norway), R. Giavazzi (Italy)
PL-17 - Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations
J. Rak (Canada)
PL-18 - Coagulation signaling and cancer immuno-therapy
W. Ruf (Germany)
PL-19 - Heparanase-revisited
Y. Nadir (Israel)
PL-20 - Cancer Animal Models in Thrombosis Research
C. Dubois (France)
PL-21 - The thrombin-inflammation axis in cancer progression
J. Palumbo (USA)
Selected Abstract
OC-09 - Thrombin Tips the Scales towards Effective Immune Checkpoint Blockade in Cancer
R. Cantrell, L. Rosenfeldt, D. Mureb, M. Lehn, B.K. Sharma, A. Revenko, B. Monia, E. Janssen, J.S. Palumbo (USA)
OC-10 - Plasminogen activator inhibitor 1 and venous thrombosis in nude mice bearing human pancreatic tumors
Y. Hisada, A. Maqsood, K. B. Garratt, B. C. Cooley, N. Mackman (USA)
10:45 – 11:45
Debate: Incidental VTE: To treat or not to treat?
Chairs: S. Siragusa (Italy), S. Middeldorp (The Netherlands)
YES: M. Di Nisio (Italy)
NO: M. Carrier (Canada)
11:45 - 12:45
Brunch
12:45 – 15:00
Plenary Session 6: Evolving Data for Treatment of VTE in cancer
Chairs: W. Ageno (Italy), G. Sof (USA)
PL-22 - Anticoagulation in Cancer Patients: advantages and disadvantages
A.J. Munoz (Spain)
PL-23 - VTE management: emerging insights from the GARFIELD VTE registry
A.J. Kakkar (UK)
PL-24 - Treatment of VTE in cancer patients: from clinical trials to real life
G. Agnelli (Italy)
PL-25 - VTE in Palliative Care Patients: What do we know?
S. Noble (UK)
Selected Abstract
OC-11 - Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study
F.T.M. Bosch, T.F. Wang, M. Di Nisio, A. Segers, J. Connors, D. Garcia, F.I. Mulder1,2, J. Weitz, H.R. Büller, M. Carrier, P. Verhamme, M. Grosso, G. Raskob, N. van Es (The Netherlands, USA)
OC-12 - Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study
F.X. Lapébie, A. Bura-Rivière, A. Merah, L. Bertoletti, M. Monreal, RIETE investigators (France, Spain)
OC-13 - Apixaban as treatment for cancer-associated venous thrombosis - The CAP study
T.L. Hannevik, J. Brekke, T. Enden, H. Frøen, H. Garresori, W. Ghanima, E.M. Jacobsen, P.Q. Paulsen, A.C. Porojnicu, A.H. Ree, P.M. Sandset, D. Torfoss, E.O. Velle, H.S. Wik, A.E.A. Dahm (Norway)
15:00 - 15:15
Concluding Remarks